Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Body Radiotherapy With Immunotherapy (Atezolizumab Plus Bevacizumab) in Patients With Advanced HCC and Major Portal Vein Tumour Thrombosis

NCT06823375 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT06823375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06823375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Body Radiotherapy With Immunotherapy (Atezolizumab Plus Bevacizumab) in Patients With Advanced HCC and Major Portal Vein Tumour Thrombosis
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2025
Completion date
July 31, 2028
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc